Article
Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection.
Journal of gastroenterology - 1 Apr 2018
Kumada Hiromitsu, Watanabe Tsunamasa, Suzuki Fumitaka, Ikeda Kenji, Sato Ken, Toyoda Hidenori, Atsukawa Masanori, Ido Akio, Takaki Akinobu, Enomoto Nobuyuki, Kato Koji, Alves Katia, Burroughs Margaret, Redman Rebecca, Pugatch David, Pilot-Matias Tami J, Krishnan Preethi, Oberoi Rajneet K, Xie Wangang, Chayama Kazuaki
Abstract excerpt
BACKGROUND: Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated pangenotypic activity and high sustained virologic response (SVR) rates in studies outside Japan. Here we report safety and efficacy in a subset of Japanese patients with chronic HCV infection who received G/P 300/120 mg in a phase 3, open-label, multicenter study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.